JAMA internal medicine

Long-term exposure to ozone linked to lung problems in smokers

Updated

Abstract

A 5-ppb increase in ozone concentration is associated with greater emphysema and air trapping among individuals with a heavy smoking history.

  • Long-term ozone exposure is linked to worse scores on the mMRC Dyspnea Scale, COPD Assessment Test, and St. George's Respiratory Questionnaire.
  • Higher ozone levels correlate with a lower percentage of post-bronchodilator forced expiratory volume in the first second of expiration (FEV1) % predicted.
  • Increased ozone exposure is associated with higher odds of experiencing respiratory exacerbations, including severe exacerbations.
  • No significant association was observed between historical ozone exposure and chronic bronchitis or measures of airway wall thickness.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Conflict of Interest Disclosures: Dr Paulin reported receiving grants from National Institute of Environmental Health Sciences (NIEHS) during the conduct of the study. Dr Gassett reported receiving grants from the National Institutes of Health (NIH) and the US Environmental Protection Agency (EPA) during the conduct of the study. Dr Kanner reported receiving a grant from the National Heart, Lung, and Blood Institute (NHLBI) during the conduct of the study. Dr Peters reported receiving grants from the NIH/NHLBI during the conduct of the study. Dr Krishnan reported receiving grants from the NIH/NHLBI during the conduct of the study. Dr Paine reported receiving grants from the NHLBI and the COPD Foundation during the conduct of the study as well as grants from the Department of Veterans Affairs outside the submitted work. Dr Dransfield reported receiving grants from the NIH during the conduct of the study; grants from the Department of Defense, American Lung Association, and Department of Veterans Affairs; and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mereo, Pulmonx, PneumRx/BTG, and Quark outside the submitted work. Dr Woodruff reported receiving grants from the NIH/NHLBI and COPD Foundation during the conduct of the study as well as personal fees from Glenmark Pharmaceuticals, Theravance, GlaxoSmithKline, NGM Pharmaceuticals, Amgen, Genentech, Regeneron, Sanofi, AstraZeneca, and 23andMe outside the submitted work. Dr Cooper reported receiving personal fees from GlaxoSmithKline outside the submitted work. Dr Barr reported receiving grants from the NIH and COPD Foundation during the conduct of the study. Dr Comellas reported receiving grants from the NIH/NHLBI, NIH/NIEHS, and NIH/National Center for Advancing Translational Sciences during the conduct of the study; personal fees from GlaxoSmithKline; and nonfinancial support from VIDA Diagnostics outside the submitted work. Dr Han reported receiving personal fees from GlaxoSmithKline, Boehringer Ingelheim, Mylan, and AstraZeneca as well as nonfinancial support from Novartis and Sunovion outside the submitted work. Dr Hoffman reported being a founder and shareholder of VIDA Diagnostics, a company commercializing lung image analysis software that was developed in part at the University of Iowa. Dr Martinez reported receiving grants from the NHLBI during the conduct of the study. Dr Peng reported receiving grants from the NIH and the EPA during the conduct of the study and personal fees from Health Effects Institute outside the submitted work. Dr Putcha reported receiving grants from the NHLBI during the conduct of the study. Dr Kaufman reported receiving grants from the NIH and the EPA during the conduct of the study. Dr Hansel reported receiving grants and personal fees from AstraZeneca and GlaxoSmithKline; grants from Boehringer Ingelheim, the NIH, and COPD Foundation; and personal fees from Mylan outside the submitted work. No other disclosures were reported.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free